Comparative Pharmacology
Head-to-head clinical analysis: DURAPHYL versus KAINAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAPHYL versus KAINAIR.
DURAPHYL vs KAINAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism; increases cAMP, relaxes bronchial smooth muscle.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
25 mg subcutaneously three times daily.
None Documented
None Documented
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Category C
Category C
Bronchodilator
Bronchodilator